Literature DB >> 31380001

Cloning and Expression of B. mellitensis bp26 Gene in Lactococcus lactis as a Food Grade Vaccine.

Maryam Azizpour Maghvan1, Parvaneh Jafari1, Seyed Davood Hoseini2, Ali Mohammad Behrozikhah3.   

Abstract

BACKGROUND: Brucellosis is still an important health problem in under developing countries and researches for finding efficient vaccine are going on. Brucella melitensis (B. mellitensis) bp26 gene is a good candidate for brucellosis vaccine and investigations showed that Lactococcus lactis (L. lactis) with several positive characteristic are attractive for protein expression as a live delivery vectors. These fast growing bacteria need no aeration, are easy to handle, have no exotoxin, endotoxin and protease, so the cost of culturing is inexpensive.
METHODS: B. mellitensis bp26 gene was cloned in food grade pNZ 8149 vector and expressed in L. lactis NZ 3900.
RESULTS: Results showed that we can produce a food-grade recombinant L. lactis producing the B. melitensis BP26 protein.
CONCLUSION: In this study, for Future evaluation about ability of L. lactis as a live delivery vector, a food-grade recombinant L. lactis producing the B. melitensis BP26 protein was produced.

Entities:  

Keywords:  Brucellosis; Exotoxins; Lactococcus lactis; Vaccines

Year:  2019        PMID: 31380001      PMCID: PMC6626509     

Source DB:  PubMed          Journal:  Avicenna J Med Biotechnol        ISSN: 2008-2835


Introduction

Brucellosis is zoonotic diseases which made health and economic problem in many countries 1. In industrialized nations because of routine screening of domestic livestock and animal vaccination brucellosis in humans and livestock are relatively uncommon. Up to now no human vaccines are available, and current animal vaccines are both virulent in humans and lack clinical efficacy 2. Therefore, an efficient, economical and easily managed vaccine needs to be developed. Researchers revealed that Brucella melitensis (B. melitensis) bp26 gene is a good immunogen and can be candidate for Brucella spp vaccine 3. This gene encoding the 28 kDa periplasmic protein is named BP26, CP28 or Omp28 and is a target molecule to detect anti-Brucella antibodies 4,5. To date, Lactococcus lactis (L. lactis) is attractive live delivery vector through mucosal routes for delivering bioactive proteins. L. lactis enters through M cells and multiplied within phagocytic cells so releasing and spreading in deeper layer was occurred. Therefore induction of immune responses against L. lactis antigens was Getting Started 6–10. PNZ8149 was used as the broad host range vector. This vector produces a cytoplasmic protein and to prevent protein removal by digestive enzymes or by other factors in the digestive tract, this protein was not designed to be secreted or attached to the cell surface of bacteria. Therefore, after entering of this recombinant bacterium through the M cells and up taking via phagocytic cells, the probability of induction the immune system, through BP26 protein, is higher 10. In this study for first time, B. mellitensis bp26 gene was cloned into the PNZ 8149 vector and expressed in L. lactis NZ 3900 for used as a research experimental tool to find a good vaccine candidate.

Materials and Methods

Bacterial strains and growth conditions

Any bacterial strains and plasmids used in this study are showed in table 1. All L. lactis strains were grown at 30°C on M17 media (Merck, Germany) containing 0.5% glucose (M17-glu) or lactose (M17-lac). All Escherichia coli (E. coli) DH5α strain were grown at 37°C on Luria-Bertani (LB) medium (Merck, Germany) containing 50 μg/ml Ampicillin or 50 μg/ml kanamycin.
Table 1.

Bacteria strains and plasmids used in this study

Strains or plasmidsRelevant characteristicsSource
Strains
E. coliDH5αHostFermentas Kit
L. lactisNZ39000HostMo Bi Tec Co
L. lactisNZ8149harboring pNZ8149 plasmidMo Bi Tec Co
E. coliDH5αharboring recombinant pET28a +bp26 plasmidOur lab preserved (3)
Plasmids
pTZ57R/TE. coliTA cloning vectorFermentas Kit
pNZ8149Food grade L. lactis lacF selection marker,Mo Bi Tec Co
Bacteria strains and plasmids used in this study

Amplification of bp26 gene

To amplify the bp26 gene, one pair of PCR primers was designed based on sequences published in Gene Bank (accession No. JF918758.1), and the restriction endonuclease sites of XbaI and SphI were added to both ends of the modified bp26 protein gene e based on the structure of PNZ8149 (forward: GCATGCATGA ACACTCGTGC and reverse: TCTAGATTACTTGAT TTCAAAAACGAC). Template DNA (pET28a+bp26) preserved by Our lab 3. The PCR was performed initial denaturation at 95°C for 2 min, followed by 34 cycles of 95°C for 1 min, 58°C for 1 min, and 72°C for 1 min. with Extra polymerization in 72°C for 30 min. The PCR product consisting 753 bp was checked using agarose gel electrophoresis and then purified using a Fermentas Silica Bead DNA Gel Extraction Kit.

Cloning and transformation

The PCR product was cloned in to pTZ57R/T vector and transformed in E. coli DH5α competent cells. The recombinant pTZ57R/T plasmid was extracted and digested with two restriction enzymes (SphI/NEB Bio lab and XbaI/Fermentas Digestion Enzyme). At the same time the pNZ8149 plasmid was digested with both SphI and XbaI and purified. The purified desire was inserted into the pNZ8149. Competent L. lactis NZ39000 cells were then electro-transformed with the recombinant plasmids (Gene e-Pulser; Bio-Rad, Hercules, CA, USA) and cultured on Elliker agarlac bromocresol purple and incubated at 30°C for 48 hr. Transformants harboring the recombinant plasmids were verified through enzymatic digestion and PCR.

Expression of recombinant protein

Expression performed according to MoBiTec NICE_ Expression_System and analyzed on 10% SDS-PAGE. To confirm the accuracy of the SDS-Page and protein expression, Western Blot was performed with Nitrocellulose Membrane (Sigma) and using the Trans-Blot SD cell (BIO-RAD). After blocking with TBST (tris-buffered saline, 0.05% Tween-20) buffer containing 5% skimmed milk at 4°C overnight, the membranes were incubated with a mouse IgG monoclonal antibody, anti-OMP28, (MyBioSource, Inc, USA) at a dilution 1:500 in phosphate-buffered saline (PBS) at a 37°C for 60 min. Then, the blots were washed and incubated with 1:2000 dilution of HRP-conjugated rabbit anti-mouse IgG (MyBioSource, Inc, USA) for 60 min. Binding was visualized using diaminobenzidine (Merck), according to the manufacturer's instruction.

Results

PCR screening

Results showed that the expected DNA band of the bp26 gene had been amplified; the PCR product was approximately 753 bp in length plus the 12 bp restriction sites (Figure 1).
Figure 1.

Colony PCR from random selected colonies on 1% agarose gel: Lane 1; Fermentas 1 Kb DNA Ladder, Lane 3, 4, 5, 6 and 7; negative colonies, Lane 2; positive colonies.

Colony PCR from random selected colonies on 1% agarose gel: Lane 1; Fermentas 1 Kb DNA Ladder, Lane 3, 4, 5, 6 and 7; negative colonies, Lane 2; positive colonies.

Digestion screening

Double-digestion confirms the size of bp26 gene (Figure 2).
Figure 2.

Double-digestion on 1% agarose gel: Lane 1; pNZ 8149, Lane 2; Fermentas 1 Kb DNA Ladder, Lane 3; pNZ 8149+ bp26 double-digestion.

Double-digestion on 1% agarose gel: Lane 1; pNZ 8149, Lane 2; Fermentas 1 Kb DNA Ladder, Lane 3; pNZ 8149+ bp26 double-digestion.

Induced expression of the recombinant L. lactis

Results of bp26 gene expression on SDS-PAGE; as it is evident in the figure, with increasing Nisin (1 ng/ml) addition time, the amount of protein expression also increases. Protein production increase with Nisin and in 5th hr the high level of protein production was seen. Results indicated that the molecular weight of the expressed recombinant protein was approximately 28 kDa (Figure 3).
Figure 3.

bp26 gene expression on SDS-PAGE: Lane 1; L. lactis with pNZ 8149 vector, Lane 2; L. lactis 3900, Lane 3; Fermentas protein Ladder, Lane 4; transformed L. lactis with recombinant pNZ 8149+bp26 vector before adding Nisin, Lane 5; transformed L. lactis with recombinant pNZ 8149+bp26 vector 1 hr after adding Nisin, Lane 6; transformed L. lactis with recombinant pNZ 8149+bp26 vector 3 hr after adding Nisin, Lane 7; transformed L. lactis with recombinant pNZ 8149+bp26 vector 5 hr after adding Nisin.

bp26 gene expression on SDS-PAGE: Lane 1; L. lactis with pNZ 8149 vector, Lane 2; L. lactis 3900, Lane 3; Fermentas protein Ladder, Lane 4; transformed L. lactis with recombinant pNZ 8149+bp26 vector before adding Nisin, Lane 5; transformed L. lactis with recombinant pNZ 8149+bp26 vector 1 hr after adding Nisin, Lane 6; transformed L. lactis with recombinant pNZ 8149+bp26 vector 3 hr after adding Nisin, Lane 7; transformed L. lactis with recombinant pNZ 8149+bp26 vector 5 hr after adding Nisin. Western blot results showed that the produced protein was the B. melitensis omp28 (Figure 4). The result show that the binding of BP26 protein and its antibody occurred.
Figure 4.

BP26 production was approved by western blot analysis. Lane 1; BP26 before adding nisin, Lane 2; BP26 production 1 hr after adding nisin, Lane 3; BP26 production 3 hr after adding nisin, Lane 4; BP26 production 5 hr after adding nisin.

BP26 production was approved by western blot analysis. Lane 1; BP26 before adding nisin, Lane 2; BP26 production 1 hr after adding nisin, Lane 3; BP26 production 3 hr after adding nisin, Lane 4; BP26 production 5 hr after adding nisin.

Discussion

Brucellosis is a worldwide zoonotic disease, which remain an important public health concern and causes economic losses in endemic areas 11,12. Vaccination is the most possible way to reduce the transmission in domestic animal herds and humans. The infectious cycles of most pathogenic micro-organisms initiate from mucosal surfaces. So, if colonization and invasion of infectious agents stopped in this stage, the infection does not happen. For this purpose, a vaccine must be made to stimulate mucosal and cellular immunity 13–15. Today, investigations showed that using Lactic Acid Bacteria (LAB) as a live delivery vectors for antigens can induce mucosal immunity and one of the most important candidates to produce mucosal vaccines. In this investigation, we used L. lactis 3900 as a gene delivery vehicle. Despite the fact that L. lactis is a non-commensal and non-colonizing bacterium at the level of the gastrointestinal tract, it can be easily taken up by M cells, and exhibits adjuvant/immune potentiating activity 16,17. As Brucella infections involve mainly bacterial entry through the mucosal routes, the development of successful approaches for oral vaccination could radically alter the current scene of brucellosis 18,19. Most published studies have evaluated the use of live vectors expressing Brucella antigens for vaccine delivery at the mucosal gut. At present, several recombinant proteins of Brucella have been evaluated as oral vaccine with L. lactis and sufficient evidence showed that they can induce protective immunity in mice 19–23. For example, in 2002, Luciana A. Ribeiro et al expressed Brucella abortus L7/L12 gene in L. lactis, under the nisin-inducible promoter 22. In another work, Daniela S. Pontes et al in 2003, revealed that a recombinant Lactococcus lactis strain producing L7/L12 under the control of nisin inducible promoter when orally administered to BALB/c mice, they could induced local humoral immune response and detected significant levels of anti-L7/L12 specific IgA in feces 21. In 2012 DarwinSáez et al, transformed Brucella abortus (B. abortus) Cu-Zn Superoxide dismutase (SOD) in L. lactis revealed that orally vaccinated mice protected against challenge with the virulent B. abortus 2308 strain 19.

Conclusion

According to the investigations which mentioned above and considering that B. melitensis BP26 is a good immunogenic protein 24, in this study, we successfully constructed a food-grade recombinant L. lactis producing the B. melitensis BP26 protein for future researches about induction of immune response by this protein.
  21 in total

Review 1.  Recent advances in mucosal vaccine development.

Authors:  H Chen
Journal:  J Control Release       Date:  2000-07-03       Impact factor: 9.776

2.  Production and targeting of the Brucella abortus antigen L7/L12 in Lactococcus lactis: a first step towards food-grade live vaccines against brucellosis.

Authors:  Luciana A Ribeiro; Vasco Azevedo; Yves Le Loir; Sergio C Oliveira; Yakhya Dieye; Jean-Christophe Piard; Alexandra Gruss; Philippe Langella
Journal:  Appl Environ Microbiol       Date:  2002-02       Impact factor: 4.792

3.  Recombinant OMP28 antigen-based indirect ELISA for serodiagnosis of bovine brucellosis.

Authors:  Pallab Chaudhuri; Rajeev Prasad; Vinoth Kumar; Arunakumar Gangaplara
Journal:  Mol Cell Probes       Date:  2009-12-16       Impact factor: 2.365

Review 4.  Heterologous protein production and delivery systems for Lactococcus lactis.

Authors:  Sébastien Nouaille; Luciana A Ribeiro; Anderson Miyoshi; Daniela Pontes; Yves Le Loir; Sergio Costa Oliveira; Philippe Langella; Vasco Azevedo
Journal:  Genet Mol Res       Date:  2003-03-31

5.  Induction of partial protection in mice after oral administration of Lactococcus lactis producing Brucella abortus L7/L12 antigen.

Authors:  Daniela S Pontes; Fernanda A Dorella; Luciana A Ribeiro; Anderson Miyoshi; Yves Le Loir; Alexandra Gruss; Sérgio C Oliveira; Philippe Langella; Vasco Azevedo
Journal:  J Drug Target       Date:  2003       Impact factor: 5.121

Review 6.  Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins.

Authors:  Luis G Bermúdez-Humarán
Journal:  Hum Vaccin       Date:  2009-04-30

Review 7.  Pathogenesis of bovine brucellosis.

Authors:  Alcina V Carvalho Neta; Juliana P S Mol; Mariana N Xavier; Tatiane A Paixão; Andrey P Lage; Renato L Santos
Journal:  Vet J       Date:  2009-09-03       Impact factor: 2.688

8.  Intranasal immunisation with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonisation in mice.

Authors:  Paola Scavone; Anderson Miyoshi; Analía Rial; Alejandro Chabalgoity; Philippe Langella; Vasco Azevedo; Pablo Zunino
Journal:  Microbes Infect       Date:  2007-03-12       Impact factor: 2.700

Review 9.  Production of hepatitis B surface antigen in recombinant plant systems: an update.

Authors:  G B Sunil Kumar; T R Ganapathi; V A Bapat
Journal:  Biotechnol Prog       Date:  2007-03-10

10.  Heterologous expression of Brucella abortus GroEL heat-shock protein in Lactococcus lactis.

Authors:  Anderson Miyoshi; Luis G Bermúdez-Humarán; Luciana A Ribeiro; Yves Le Loir; Sérgio C Oliveira; Philippe Langella; Vasco Azevedo
Journal:  Microb Cell Fact       Date:  2006-03-23       Impact factor: 5.328

View more
  1 in total

Review 1.  Plasmid Replicons for the Production of Pharmaceutical-Grade pDNA, Proteins and Antigens by Lactococcus lactis Cell Factories.

Authors:  Sofia O D Duarte; Gabriel A Monteiro
Journal:  Int J Mol Sci       Date:  2021-01-30       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.